Johnson & Johnson's one-dose coronavirus vaccine performed well in its recent trial, according to CNBC.
The vaccine candidate appeared to generate a promising immune response in volunteers of all ages, according to trial data published Wednesday in the New England Journal of Medicine. The vaccine is called Ad26.COV2.S and was administered to individuals between the ages of 18 and 55 and those 65 and older. Some participants were given a placebo while others were given the real vaccine.
Most of the volunteers generated neutralizing antibodies after 28 days, according to the trial data. By day 57, all of the volunteers had generated antibodies. However, there were significant side effects such as fever, fatigue, headache, muscle aches, and pain at the point of injection.
This trial consisted of 805 volunteers. J&J is expected to release results from its 45,000-person phase three trial later this month. The vaccine could be authorized as early as next month.
Johnson & Johnson's vaccine only requires one dose. This is different than the Pfizer and Moderna vaccine that have already been granted emergency authorization approval and require two doses. This would simplify logistics for sites that administer shots and allow the vaccine to be rolled out at a faster pace.